| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 02/08/1999 | CA2239223A1 Novel rpoa |
| 02/08/1999 | CA2239222A1 Novel rpoa |
| 02/06/1999 | CA2239256A1 Novel lgt |
| 02/05/1999 | CA2239817A1 Novel prokaryotic polynucleotides, polypeptides and their uses |
| 02/05/1999 | CA2239270A1 Novel phosphoribosyl transferase |
| 02/05/1999 | CA2238673A1 Novel aminopeptidase |
| 02/05/1999 | CA2212315A1 Pharmaceutical composition with neurotrophic-like biological activity |
| 02/04/1999 | WO1999005527A2 Methods for diagnosis and therapy of autoimmune disease, such as insulin dependent diabetes mellitus, involving retroviral superantigens |
| 02/04/1999 | WO1999005502A2 Modulation of multicellular aggregates by solid stress |
| 02/04/1999 | WO1999005307A1 Sel-10 AND USES THEREOF |
| 02/04/1999 | WO1999005302A1 Conjugates of transporter peptides and nucleic acid analogs, and their use |
| 02/04/1999 | WO1999005300A2 Ghrh expression system and methods of use |
| 02/04/1999 | WO1999005299A1 Methods of using cytochrome p450 reductase for the enhancement of p450-based anti-cancer gene therapy |
| 02/04/1999 | WO1999005294A1 INTRACELLULAR INHIBITORS OF Gq PROTEIN SIGNALING |
| 02/04/1999 | WO1999005291A2 Aggrecan degrading metallo proteases |
| 02/04/1999 | WO1999005289A1 Recombinant lysostaphin analogs |
| 02/04/1999 | WO1999005280A1 Mammalian cytokine: interleukin-b30 and related reagents |
| 02/04/1999 | WO1999005279A1 Mcp-1 analogs |
| 02/04/1999 | WO1999005278A1 Lens epithelial cell derived growth factor |
| 02/04/1999 | WO1999005275A1 Secreted proteins encoded by human chromosome 13 |
| 02/04/1999 | WO1999005272A1 Use of transcription factor brn-3a |
| 02/04/1999 | WO1999005270A2 Crustacean antimicrobial peptides, called penaiedines |
| 02/04/1999 | WO1999005269A2 Transcriptional silencer protein nrf |
| 02/04/1999 | WO1999005268A1 Production of erythropoietin by endogenous gene activation |
| 02/04/1999 | WO1999005267A1 Identification of human cell lines for the production of human proteins by endogenous gene activation |
| 02/04/1999 | WO1999005264A2 Production of human mutant proteins in human cells by homologous recombination |
| 02/04/1999 | WO1999005263A1 Anti-invasive and anti-angiogenic urokinase fragments and their use |
| 02/04/1999 | WO1999005258A1 HUMAN Nkx POLYPEPTIDE-ENCODING NUCLEIC ACIDS AND TRANSGENIC ANIMALS DERIVED THEREFROM |
| 02/04/1999 | WO1999005255A1 Methods for enhancing or reducing preimplantation embryo survival rates |
| 02/04/1999 | WO1999005180A1 Collagen type i and type iii adhesive compositions |
| 02/04/1999 | WO1999005177A1 Methods and compositions for identifying modulators of g-protein-coupled receptors |
| 02/04/1999 | WO1999005175A2 Diagnosis and treatment of diseases using anti-anti-t-cell receptor vbeta anti-bodies or peptides which are recognized by said antibodies, and endocrine secretion regulatory protein i (esrp1) |
| 02/04/1999 | WO1999005174A1 The ha-1 antigen |
| 02/04/1999 | WO1999005173A1 The ha-1 antigen |
| 02/04/1999 | WO1999005171A1 NOVEL ESTROGEN RECEPTOR β AND ISOFORMS |
| 02/04/1999 | WO1999005170A1 NOVEL ESTROGEN β RECEPTOR AND ISOFORMS |
| 02/04/1999 | WO1999005165A1 Streptogramines, their preparation and compositions containing them |
| 02/04/1999 | WO1999005162A1 Methods of modifying the butyrophilin protein to eliminate an autoimmune response and products associated therewith |
| 02/04/1999 | WO1999005161A1 HUMAN PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA (PPARη) GENE REGULATORY SEQUENCES AND USES THEREFOR |
| 02/04/1999 | WO1999004837A1 Blood product delivery system |
| 02/04/1999 | WO1999004825A1 Methods and compositions for the diagnosis and treatment of neuropsychiatric disorders |
| 02/04/1999 | WO1999004820A2 Cytolysis of target cells by superantigen conjugates inducing t-cell activation |
| 02/04/1999 | WO1999004813A1 Receptor specific transepithelial transport of therapeutics |
| 02/04/1999 | WO1999004810A2 Use of mhc class ii ligands as adjuvant for vaccination and of lag-3 in cancer treatment |
| 02/04/1999 | WO1999004809A1 Pharmaceutical compositions containing lysostaphin alone or in combination with an antibiotic for the treatment of staphylococcal infections |
| 02/04/1999 | WO1999004808A1 Dental remedies containing pth |
| 02/04/1999 | WO1999004807A1 Recombinant immunotoxin containing a diphterial toxin and interleukin -2(dt482-il2) and method for preparing the same |
| 02/04/1999 | WO1999004806A1 Methods and compositions for inhibiting angiogenesis |
| 02/04/1999 | WO1999004800A1 Nucleic acid compositions and methods of introducing nucleic acids into cells |
| 02/04/1999 | WO1999004795A1 Delta opioid receptor agonist for reducing ischemic damage |
| 02/04/1999 | WO1999004775A2 Method of treating dopaminergic and gaba-nergic disorders |
| 02/04/1999 | WO1999004764A1 Tannic acid-polymer compositions for controlled release of pharmaceutical agents, particularly in the oral cavity |
| 02/04/1999 | WO1999004761A1 Method of preparing pharmaceutical compositions of lipid particles comprising a lipid agent and a protein |
| 02/04/1999 | WO1999004752A2 Methods for treating skin pigmentation |
| 02/04/1999 | WO1998051782A3 Human 3-hydroxyisobutyryl-coenzyme a hydrolase |
| 02/04/1999 | WO1998051337A3 Immunogenic compositions to the cck-b/gastrin-receptor and methods for the treatment of tumors |
| 02/04/1999 | WO1998050546A3 B cell receptor associated proteins |
| 02/04/1999 | WO1998050433A3 Human monoclonal antibodies to epidermal growth factor receptor |
| 02/04/1999 | WO1998050424A3 Human serine protease precursor |
| 02/04/1999 | WO1998050079A3 Techniques and compositions for treating heart failure and ventricular remodeling by in vivo delivery of angiogenic transgenes |
| 02/04/1999 | WO1998049287A3 Antisense oligonucleotides specific for thymidylate synthase |
| 02/04/1999 | WO1998048821A3 Use of conantokins for producing analgesia or for neuroprotection |
| 02/04/1999 | DE19832405A1 Isolation of N6-tri:fluoro-acetyl-lisinopril ethyl ester from aqueous solutions |
| 02/04/1999 | DE19732944A1 Derivatives of calcitonin-gene-related peptide fragment |
| 02/04/1999 | CA2732570A1 Use of mhc class ii ligands as adjuvant for vaccination and of lag-3 in cancer treatment |
| 02/04/1999 | CA2308146A1 Collagen type i and type iii adhesive compositions |
| 02/04/1999 | CA2305624A1 Recombinant lysostaphin analogs |
| 02/04/1999 | CA2299514A1 Streptogramines, their preparation and compositions containing them |
| 02/04/1999 | CA2298930A1 Pharmaceuticals for modulating hormone responsiveness |
| 02/04/1999 | CA2298887A1 The ha-1 antigen |
| 02/04/1999 | CA2298474A1 Methods and compositions for the diagnosis and treatment of neuropsychiatric disorders |
| 02/04/1999 | CA2298410A1 Intracellular inhibitors of gq protein signaling |
| 02/04/1999 | CA2298107A1 Use of transcription factor brn-3a |
| 02/04/1999 | CA2298067A1 Conjugates of transporter peptides and nucleic acid analogs, and their use |
| 02/04/1999 | CA2298053A1 Novel estrogen receptor .beta. and isoforms |
| 02/04/1999 | CA2298015A1 Production of erythropoietin by endogenous gene activation |
| 02/04/1999 | CA2297946A1 Sel-10 and uses thereof |
| 02/04/1999 | CA2297907A1 Human estrogen receptor beta |
| 02/04/1999 | CA2297491A1 Methods for diagnosis and therapy of autoimmune disease, such as insulin dependent diabetes mellitus, involving retroviral superantigens |
| 02/04/1999 | CA2297410A1 Method of treating dopaminergic and gaba-nergic disorders |
| 02/04/1999 | CA2297375A1 Ghrh expression system and methods of use |
| 02/04/1999 | CA2297251A1 Delta opioid receptor agonist for reducing ischemic damage |
| 02/04/1999 | CA2296798A1 Directed cytolysis of target cells, agents and compositions causing cytolysis, and compounds that can be used to produce the agents |
| 02/04/1999 | CA2296654A1 Tannic acid-polymer compositions for controlled release of pharmaceutical agents, particularly in the oral cavity |
| 02/04/1999 | CA2296292A1 Secreted proteins encoded by human chromosome 13 |
| 02/04/1999 | CA2269772A1 Anti-invasive and anti-angiogenic urokinase fragments and their use |
| 02/04/1999 | CA2267077A1 Methods for treating skin pigmentation |
| 02/04/1999 | CA2239267A1 Novel compounds |
| 02/03/1999 | EP0894863A1 A YAK-1 related serine/threonine protein kinase-HTLAR33 |
| 02/03/1999 | EP0894862A2 Novel CysS |
| 02/03/1999 | EP0894861A2 Glycogen phosphorylase from Streptococcus pneumoniae |
| 02/03/1999 | EP0894859A2 Asparaginyl tRNA synthetase from Streptococcus pneumoniae |
| 02/03/1999 | EP0894858A2 Prolyl tRNA synthetase from Streptococcus pneumoniae |
| 02/03/1999 | EP0894857A2 SecA gene from Streptococcus pneumoniae |
| 02/03/1999 | EP0894856A1 A human sMAD3 splice variant |
| 02/03/1999 | EP0894855A2 Human I kappa B-beta transcription factor |
| 02/03/1999 | EP0894854A2 A novel splicing variant of the epstein-barr virus-induced g-protein coupled receptor |
| 02/03/1999 | EP0894853A1 Transcriptional silencer protein NRF, nucleic acid molecules encoding it and their use |
| 02/03/1999 | EP0894807A1 GPIb-LIPID COMPLEX AND USES THEREOF |
| 02/03/1999 | EP0894806A1 Novel pheS |